new glp 1 drugs in development FORMULATION 9 Companies Developing Next-Generation GLP-1

The results varied significantly in severity

Peptide therapy should only be used under medical supervision

Ipamorelin produces brief, high GH peaks (hours)

This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health

This allows sermorelin to be administered either intravenously or subcutaneously and promotes GH secretion from the pituitary gland without affecting other hormones such as insulin, cortisol, glucose, glucagon, luteinizing hormone, or follicle-stimulating hormone

Patients with a history of allergic reactions to similar compounds or excipients present in the preserved formulation should exercise caution